Clinical trial
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
NCT00142129 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00142129 |
|---|---|
| Title | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Velcade in Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib (Velcade) |
| Enrollment | 27 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Jun 27, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: